Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CLDX

Celldex Therapeutics Inc

Dec 13 • 04:00PM ET

25.41

Dollar change -1.04
Percentage change -3.93	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK REGN GILD VRTX INCY AMGN BIIB JNJ PFE

| Held by: VTI IWM VXF XBI IWO SCHA VTWO VHT IWN ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.57	Insider Own	2.48%	Shs Outstand	66.34M	Perf Week	-5.08%
Market Cap	1.62B	Forward P/E	-	EPS next Y	-3.23	Insider Trans	-2.12%	Shs Float	64.70M	Perf Month	-5.33%
Income	-154.08M	PEG	-	EPS next Q	-0.73	Inst Own	107.44%	Short Float	11.90%	Perf Quarter	-40.71%
Sales	9.98M	P/S	162.28	EPS this Y	15.95%	Inst Trans	3.63%	Short Ratio	6.34	Perf Half Y	-26.71%
Book/sh	11.85	P/B	2.15	EPS next Y	-31.77%	ROA	-27.93%	Short Interest	7.70M	Perf Year	-26.73%
Cash/sh	11.78	P/C	2.16	EPS next 5Y	-	ROE	-29.84%	52W Range	22.93 - 53.18	Perf YTD	-35.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.41%	ROI	-19.56%	52W High	-52.22%	Beta	1.60
Dividend TTM	-	Quick Ratio	24.27	Sales past 5Y	30.09%	Gross Margin	68.76%	52W Low	10.82%	ATR (14)	1.43
Dividend Ex-Date	-	Current Ratio	24.27	EPS Y/Y TTM	2.69%	Oper. Margin	-1745.97%	RSI (14)	42.21	Volatility	5.26% 5.42%
Employees	160	Debt/Eq	0.00	Sales Y/Y TTM	128.55%	Profit Margin	-1544.48%	Recom	1.33	Target Price	67.10
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	21.52%	Payout	-	Rel Volume	0.86	Prev Close	26.45
Sales Surprise	281.88%	EPS Surprise	4.83%	Sales Q/Q	110.35%	Earnings	Nov 06 AMC	Avg Volume	1.22M	Price	25.41
SMA20	-3.45%	SMA50	-7.02%	SMA200	-29.09%	Trades		Volume	1,040,099	Change	-3.93%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Initiated	Citigroup	Buy	$70
Sep-30-24	Initiated	Goldman	Neutral	$45
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy	$58
Jun-11-24	Initiated	Wolfe Research	Outperform	$51
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$27
Aug-22-23	Initiated	Wells Fargo	Underweight	$21
Sep-17-21	Initiated	Jefferies	Buy	$66
Sep-10-21	Initiated	SVB Leerink	Outperform	$68
Jul-22-21	Initiated	Guggenheim	Buy	$66
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight	$8
Aug-01-17	Resumed	H.C. Wainwright	Buy	$10
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral	$4
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Mar-07-16	Downgrade	Guggenheim	Buy → Neutral
Mar-01-16	Initiated	H.C. Wainwright	Buy	$25
Aug-11-15	Reiterated	ROTH Capital	Buy	$43 → $39

Show Previous Ratings

Nov-20-24 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases (GlobeNewswire) +5.68%
Nov-11-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 05:30PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.65%
04:25PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
12:05PM	Loading…
Oct-29-24 12:05PM	Celldex selloff creates buying opportunity, says Guggenheim (TipRanks)
Oct-26-24 05:43PM	Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire)
Oct-25-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 (GlobeNewswire)
Oct-23-24 08:39AM	Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results (Insider Monkey)
Oct-15-24 06:10PM	Celldex Therapeutics, Inc. (CLDX): Hedge Funds Hidden Gem in Small-Cap Stocks (Insider Monkey)
Sep-25-24 10:45AM	Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 (GlobeNewswire) -12.06%
Sep-16-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 (GlobeNewswire)
Sep-14-24 05:18PM	Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-12-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.77%
Aug-08-24 05:25PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Loading…
04:20PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-24 04:01PM	Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire) -5.77% -8.45%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 08:01AM	Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jun-11-24 07:00PM	Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ... (GuruFocus.com)
Jun-04-24 04:01PM	Celldex Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-02-24 09:01AM	Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 (GlobeNewswire)
May-27-24 09:55AM	Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet (Zacks)
May-15-24 11:33AM	Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study (MT Newswires)
08:01AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis (GlobeNewswire)
May-09-24 09:55AM	Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade (Zacks)
May-06-24 09:55PM	CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:22PM	Celldex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:01AM	Loading…
Apr-17-24 08:01AM	Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria (GlobeNewswire)
Apr-09-24 09:35AM	Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) (Zacks)
Apr-08-24 12:00PM	All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy (Zacks)
09:35AM	Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) (Zacks)
Mar-20-24 09:55AM	Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect? (Zacks)
Mar-08-24 07:00AM	Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 10:30AM	Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
10:10AM	Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-29-24 09:14PM	Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock (GlobeNewswire) -6.44% +7.95%
12:00PM	Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know (Zacks)
Feb-28-24 04:01PM	Celldex Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-26-24 04:03PM	Celldex Stock Rockets 28% On A Promising New Hives Treatment (Investor's Business Daily) +27.76% +5.83%
12:11PM	Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment (Investor's Business Daily)
08:10AM	Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:19AM	Celldex: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-24-24 02:05PM	Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria (GlobeNewswire)
Feb-20-24 08:26AM	TipRanksPerfect 10 List: These 2 Biotech Stocks Look Compelling at Current Levels (TipRanks)
Feb-06-24 04:01PM	Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-05-24 08:01AM	Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 (GlobeNewswire)
Nov-27-23 04:15PM	Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-17-23 01:08PM	Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare (InvestorPlace)
Nov-07-23 11:15PM	Celldex Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -8.68%
04:01PM	Celldex Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-23 06:47PM	Why Celldex Therapeutics Blasted 13% Higher on Monday (Motley Fool) +12.97%
04:01PM	Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi (Investor's Business Daily)
12:15PM	Freshpet, Celldex Therapeutics rise; TreeHouse Foods, Dish Network fall, Monday, 11/6/2023 (Associated Press)
07:00AM	Celldexs reinvention advances with inflammatory disease drug data (BioPharma Dive)
06:30AM	Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-05-23 03:00PM	Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab (GlobeNewswire)
Nov-04-23 05:39AM	Celldex Therapeutics Inc (CLDX) Q3 2023 Earnings: R&D Expenses Rise Amid Progress in ... (GuruFocus.com)
Nov-02-23 04:25PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance) +8.20%
04:01PM	Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-26-23 07:01AM	Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023 (GlobeNewswire)
Sep-25-23 08:31AM	Celldex Therapeutics to Present at Cantor Global Healthcare Conference (GlobeNewswire)
Aug-22-23 09:35AM	AppLovin upgraded, Genpact downgraded: Wall Street's top analyst calls (The Fly) -5.20%
Aug-08-23 05:30PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.83%
04:21PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-11-23 08:01AM	Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jul-06-23 08:01AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (GlobeNewswire)
Jun-10-23 10:45AM	Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023 (GlobeNewswire)
Jun-08-23 04:01PM	Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023 (GlobeNewswire)
Jun-02-23 08:01AM	Celldex Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies (GlobeNewswire)
May-23-23 06:10AM	Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-15-23 08:01AM	Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023 (GlobeNewswire)
May-04-23 06:05PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.68%
05:03PM	Celldex: Q1 Earnings Snapshot (AP Finance)
04:01PM	Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-18-23 05:58AM	Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength? (Zacks) +5.92%
Apr-12-23 08:13AM	Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%? (Simply Wall St.)
Mar-29-23 09:01AM	Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-02-23 05:40AM	Celldex Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Feb-28-23 04:01PM	Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.51%
Feb-27-23 10:25AM	Why Celldex Therapeutics Shares Are Trading Higher Today (Benzinga) +7.30%
Feb-26-23 09:00AM	Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023 (GlobeNewswire)
Feb-16-23 04:01PM	Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors (GlobeNewswire)
Feb-15-23 07:00AM	Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-03-23 07:01AM	Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 (GlobeNewswire)
Jan-18-23 02:38PM	As Celldex Recovers, Here's My Strategy (TheStreet.com)
Dec-06-22 06:00AM	Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022 (GlobeNewswire)
Dec-02-22 09:31AM	Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022 (GlobeNewswire)
Nov-27-22 09:45AM	We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely (Simply Wall St.)
Nov-10-22 04:01PM	Celldex to Participate in Upcoming November Investor Conferences (GlobeNewswire) +15.99%
Nov-09-22 05:25PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.67%
04:01PM	Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 10:01AM	Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marucci Anthony S	PRESIDENT & CEO	Nov 11 '24	Buy	26.82	11,500	308,430	40,284	Nov 12 08:01 AM
Martin Samuel Bates	SVP AND CFO	Jun 14 '24	Option Exercise	10.16	20,169	204,990	45,297	Jun 18 04:05 PM
Martin Samuel Bates	SVP AND CFO	Jun 14 '24	Sale	35.42	17,172	608,315	28,125	Jun 18 04:05 PM
Crowley Elizabeth	SR. VP & CPDO	Jun 14 '24	Option Exercise	10.38	30,000	311,400	39,074	Jun 18 04:04 PM
Crowley Elizabeth	SR. VP & CPDO	Jun 14 '24	Sale	34.87	30,000	1,045,962	9,074	Jun 18 04:04 PM
Young Diane C.	SVP, CHIEF MEDICAL OFFICER	Jun 11 '24	Option Exercise	2.71	15,000	40,650	17,115	Jun 13 04:05 PM
Crowley Elizabeth	SR. VP & CPDO	Jun 07 '24	Option Exercise	9.70	15,000	145,474	24,074	Jun 11 04:02 PM
Crowley Elizabeth	SR. VP & CPDO	Jun 07 '24	Sale	35.06	15,000	525,873	9,074	Jun 11 04:02 PM
Young Diane C.	SVP, CHIEF MEDICAL OFFICER	Jun 07 '24	Sale	35.26	45,000	1,586,844	2,115	Jun 11 04:01 PM
Jimenez Freddy A.	SVP & GENERAL COUNSEL	Jun 05 '24	Option Exercise	10.38	9,540	99,025	35,464	Jun 07 04:05 PM
Heath-Chiozzi Margo	SVP OF REGULATORY AFFAIRS	Jun 03 '24	Option Exercise	10.25	64,658	662,575	71,752	Jun 05 04:06 PM
Heath-Chiozzi Margo	SVP OF REGULATORY AFFAIRS	Jun 03 '24	Sale	33.65	58,369	1,964,088	13,383	Jun 05 04:06 PM
Wright Richard M.	SR. VP & CCO	Jun 03 '24	Option Exercise	18.79	67,469	1,267,540	67,677	Jun 05 04:05 PM
Wright Richard M.	SR. VP & CCO	Jun 03 '24	Sale	33.72	46,844	1,579,353	20,833	Jun 05 04:05 PM
Jimenez Freddy A.	SVP & GENERAL COUNSEL	Jun 03 '24	Option Exercise	10.38	8,006	83,102	33,930	Jun 05 04:04 PM
Jimenez Freddy A.	SVP & GENERAL COUNSEL	Jun 03 '24	Sale	33.60	8,006	269,002	25,924	Jun 05 04:04 PM
Heath-Chiozzi Margo	SVP OF REGULATORY AFFAIRS	May 30 '24	Option Exercise	3.75	33,719	126,301	45,813	Jun 03 04:06 PM
Heath-Chiozzi Margo	SVP OF REGULATORY AFFAIRS	May 30 '24	Sale	34.07	38,719	1,319,156	7,094	Jun 03 04:06 PM
Martin Samuel Bates	SVP AND CFO	May 30 '24	Option Exercise	10.38	25,000	259,500	60,128	Jun 03 04:05 PM
Martin Samuel Bates	SVP AND CFO	May 30 '24	Sale	34.05	35,000	1,191,774	25,128	Jun 03 04:05 PM
Cavanaugh Sarah	SVP OF CORP AFFAIRS & ADMIN.	May 30 '24	Option Exercise	5.80	20,853	120,979	22,713	Jun 03 04:04 PM
Cavanaugh Sarah	SVP OF CORP AFFAIRS & ADMIN.	May 30 '24	Sale	33.73	20,853	703,334	1,860	Jun 03 04:04 PM
Crowley Elizabeth	SR. VP & CPDO	May 30 '24	Option Exercise	4.01	42,945	172,397	47,671	Jun 03 04:04 PM
Crowley Elizabeth	SR. VP & CPDO	May 30 '24	Sale	33.64	38,597	1,298,384	9,074	Jun 03 04:04 PM
Jimenez Freddy A.	SVP & GENERAL COUNSEL	Feb 13 '24	Option Exercise	3.86	24,166	93,163	25,924	Feb 15 04:05 PM
Martin Samuel Bates	SVP AND CFO	Jan 02 '24	Option Exercise	2.78	10,750	29,885	35,128	Jan 04 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDX

Celldex Therapeutics Inc

Upgrade your FINVIZ experience